Abstract: The present invention relates to inhibitors of KRAS oncogene activation, which are flavagline derivatives with the ability to target prohibitin to inhibit KRAS activation. The flavagline derivatives according to the invention have the general formula (I) in which R1 is —HO, —COO, —C(NH)O, —CO(NH)N—(CH3)2, —CO(NH)(NH2); R2 is —H, —COO—CH3, —CO(NH)—CH3, —NO(CH3)2; R3, R4, R5 are each independently —H, —OH; R6 is —H, —OH, —F; R7 is —H, —OH; R8 is —H, —OCH3, —Br, —F, —Cl; R9 is —O—CH3, —O—(CH2)2—NH—CH3. The invention further relates to pharmaceutical compositions comprising one or more of said flavagline derivatives and the use in methods for inhibition of KRAS activation.